Welcome to our dedicated page for Wearable Devices Ltd. SEC filings (Ticker: WLDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wearable Devices Ltd. (WLDS) SEC filings page on Stock Titan aggregates the company’s public reports as a foreign private issuer, giving investors structured access to its regulatory disclosures. Wearable Devices files primarily on Form 6-K under the Securities Exchange Act of 1934, and these reports often attach press releases or transaction documents that explain key corporate and financing events.
Recent 6-K filings describe registered direct offerings of ordinary shares and pre-funded warrants, concurrent private placements of ordinary warrants, and an at-the-market sales agreement for ordinary shares. These filings outline terms such as offering structures, use of registration statements on Form F-3, warrant exercise conditions, lock-up provisions and commission arrangements with placement agents or sales agents. Other 6-Ks cover matters like annual and special general meetings, amendments to the company’s compensation policy, and increases in authorized share capital through changes to its articles of association.
For those analyzing WLDS, the filings also reference clinical and technology milestones when they are furnished as exhibits, such as the neurorehabilitation pilot with Soroka University Medical Center and grant support from the Israel Innovation Authority. While detailed financial statements are not included in the excerpts provided here, the 6-K framework allows the company to incorporate press releases and legal opinions by reference into existing registration statements on Form F-3 and Form S-8.
On Stock Titan, users can review these WLDS filings in chronological order and use AI-powered summaries to interpret complex legal and transactional language. The platform highlights essential elements of each report—such as the nature of an offering, key conditions, and referenced exhibits—so readers can more quickly understand how each filing relates to Wearable Devices’ capital structure, governance decisions and product-related disclosures.
Wearable Devices Ltd. entered a warrant inducement transaction with an institutional investor, raising approximately $5.0 million in gross cash proceeds through the cash exercise of existing warrants at a reduced price of $1.73 per ordinary share.
In return, the company issued new unregistered warrants to purchase up to 5,082,873 ordinary shares at an exercise price of $1.51 per share, exercisable immediately for five years. The company plans to use the net proceeds for working capital and general corporate purposes and agreed to register the resale of the new warrant shares and observe a 30‑day restriction on additional issuances, new registrations, and variable rate transactions, subject to stated exceptions.
Wearable Devices Ltd. director Bachar Eli filed an initial ownership report showing direct holdings in both ordinary shares and stock options. He reports 37,884 Ordinary Shares held directly, plus stock options over 768 Ordinary Shares at an exercise price of $0.7200 per share expiring on November 27, 2027, and options over 83 Ordinary Shares at an exercise price of $316.8000 per share expiring on November 30, 2033. Footnotes indicate additional equity incentives, including 7,500 Ordinary Shares issuable from 2,500 restricted share units vesting through October 10, 2028, and 28,333 Ordinary Shares issuable from other restricted share units vesting in 34 monthly installments through January 1, 2029.
Wearable Devices Ltd. Chief Executive Officer Asher Dahan filed an initial Form 3, reporting his current equity stake in the company. He directly holds 72,708 Ordinary Shares, reflecting his existing ownership position as of the filing date.
In addition, Dahan holds stock options over 125 Ordinary Shares at an exercise price of $316.80 per share expiring on November 30, 2033, and options over 208 Ordinary Shares at an exercise price of $104.16 per share expiring on September 26, 2034. Footnotes state that his holdings include 6,250 Ordinary Shares issuable upon vesting of RSUs in monthly installments through September 10, 2026, and 47,222 Ordinary Shares issuable upon vesting of RSUs in monthly installments through January 1, 2029, with each RSU representing one Ordinary Share.
Wearable Devices Ltd. director and executive officer Wagner Guy filed an initial ownership report showing his equity position in the company. He directly holds 74,583 Ordinary Shares, along with restricted share units that can convert into additional shares over time as they vest.
The filing also lists two stock option awards. One option covers 125 Ordinary Shares at an exercise price of 316.8000, vesting partly on August 23, 2024 and then in monthly installments. A second option covers 208 Ordinary Shares at an exercise price of 104.1600, vesting from August 15, 2025 in monthly installments. The document records these as holdings, not new market purchases or sales.
Wearable Devices Ltd. filed an initial ownership report for Chief Technology Officer Langer Leeor Jacob. He directly holds 72,917 Ordinary Shares and stock options to acquire 125 additional Ordinary Shares at an exercise price of 316.8 per share, expiring on August 23, 2033.
The filing notes 6,250 Ordinary Shares issuable upon vesting of restricted share units in equal monthly installments of 1,042 shares through September 10, 2026, and 47,222 Ordinary Shares issuable upon vesting of restricted share units in equal monthly installments of 1,389 shares through January 1, 2029.
Wearable Devices Ltd. executive Remez Offir has filed an initial Form 3 showing his equity holdings in the company. The filing reports direct ownership of 25,417 Ordinary Shares as of the reporting date, establishing his baseline stake as Executive VP of Business Development.
Offir also holds stock options over 571 Ordinary Shares at an exercise price of $0.72 per share expiring on November 1, 2031, and options over 83 Ordinary Shares at an exercise price of $316.80 per share expiring on November 30, 2033. Footnotes indicate additional equity incentives through restricted share units: 2,500 Ordinary Shares vesting in equal monthly installments of 417 shares through September 10, 2026, and 16,528 Ordinary Shares vesting in equal monthly installments of 486 shares through January 1, 2029, with each RSU convertible into one Ordinary Share.
Wearable Devices Ltd. filed a post-effective amendment to register up to 33,644 ordinary shares issuable upon exercise of outstanding IPO Warrants and Underwriter’s Warrants originally issued in the company’s 2022 IPO. The filing covers 32,863 IPO Warrant shares and 781 Underwriter’s Warrant shares.
The company states it would receive up to $15.8 million in net proceeds if all IPO Warrants are exercised (assuming the adjusted $480.00 exercise price) and up to $995 thousand if all Underwriter’s Warrants are exercised. Shares outstanding were 3,597,740 Ordinary Shares as of March 22, 2026.
Wearable Devices Ltd. director Ilana Lurie filed an initial ownership report showing her equity stake in the company. She directly holds 37,500 Ordinary Shares. This amount includes 7,500 shares issuable from 2,500 restricted share units (RSUs) that begin vesting on October 10, 2026 and then in equal monthly installments through October 10, 2028, and 28,333 shares issuable from RSUs vesting in equal monthly installments of 833 shares through January 1, 2029, with each RSU representing one Ordinary Share.
She also holds a stock option covering 83 Ordinary Shares at an exercise price of 316.8000, which was granted on November 30, 2023, vests in monthly installments after an initial vesting on August 23, 2024, and expires on November 30, 2033.